RxDoctor Payments Data

Fernando Arzola, MD

Cardiovascular Disease · Piedmont, MONPI 1275530065

Payments from drug & device makers

$3,055in general payments, 2019–2025

Across 140 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Amgen$638
  • Novartis$281
  • E.r. Squibb & Sons, L.L.C.$198
  • AstraZeneca$141
  • Bayer$125
  • plus $594 from 9 others

What the payments were for

  • Food & beverage$3,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,055 in reported general payments places this provider in the 55th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$54,550
Medicare patients
3,283
Services billed
4,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$26,596
EntrestoSacubitril/Valsartan13$15,143
XareltoRivaroxaban22$15,112
EliquisApixaban12$12,708
Nitroglycerin30$457
Metoprolol Succinate32$328
Rosuvastatin Calcium20$226
Isosorbide Mononitrate ErIsosorbide Mononitrate18$220
Atorvastatin Calcium34$187
Carvedilol19$95
Lisinopril15$56
Spironolactone14$55
Losartan Potassium11$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$109$26,59623 claims
NovartisEntresto$281$15,14313 claims
Johnson & JohnsonXarelto$1,077$15,11222 claims
PfizerEliquis$15$12,70812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Piedmont

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →